While the results remain to be replicated in larger studies, the researchers caution, these early findings raise hope that an anti-tumor vaccine is feasible for treatment of patients with kidney cancer at high risk of recurrence.
“We’re very excited about these results, which show such a positive response in all nine patients with kidney cancer,” says co-senior author and co-principal investigator Toni Choueiri, the HMS Jerome and Nancy Kohlberg Chair and Professor of Medicine and director of the Lank Center for Genitourinary Cancer at Dana-Farber.
The vaccines, designed to train the body’s immune system to recognize and destroy cancer, were administered after surgery to eliminate any remaining tumor cells. At the time researchers paused data collection, all nine…